1. Checkpoint Inhibitors in First-Line Advanced NSCLC

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Checkpoint Inhibitors in NSCLC

5. Early Checkpoint Immunotherapy Findings in the Front-Line Setting

6. KEYNOTE 024 First-Line Monotherapy

7. KEYNOTE-021 Cohort G First-Line Combination Therapy

8. Patient Scenario

9. Considerations for Use of First-Line Combination Therapy (cont)

10. Patient Scenario

11. Maintenance Therapy for Front-Line Combination Therapy

12. PD-L1 Testing for First-Line Decisions

13. Patient Scenario

14. Best Practices for Managing Toxicity

15. Considerations for Rechallenge After Toxicity

16. Patient Scenario

17. Additional Monotherapy Investigations

18. Results With PD-1/CTLA-4 Inhibition

19. Ongoing First-Line Clinical Trials

20. Clinical Pearls

21. Abbreviations